In thyroid cancer, CTNNBIP1 functions as a negative regulator of the Wnt/β-catenin pathway by decreasing the interaction between β-catenin and TCF/LEF to inhibit the expression of downstream target proteins. Here, HNF4A is linked to thyroid cancer.